Scarica l'app Stockscreener
103.78
0.11%
0.11
Dopo l'orario di chiusura:
103.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$103.67
Aprire:
$101.59
Volume 24 ore:
600.01K
Relative Volume:
0.76
Capitalizzazione di mercato:
$6.62B
Reddito:
$46.02M
Utile/perdita netta:
$-130.15M
Rapporto P/E:
-50.81
EPS:
-2.0427
Flusso di cassa netto:
$56.08M
1 W Prestazione:
+1.58%
1M Prestazione:
+10.12%
6M Prestazione:
+59.71%
1 anno Prestazione:
+115.31%
Intervallo 1D:
$101.59
$104.31
Intervallo di 1 settimana:
$97.89
$107.84
Portata 52W:
$39.60
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
103.78 | 6.62B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Jobs Data: Will Protagonist Therapeutics Inc benefit from AI trends2026 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Protagonist Therapeutics, Inc. (PTGX) stock price, news, quote and history - Yahoo Finance Australia
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
This Healthcare Stock Barely Flinches During Market Sell-Offs - The Motley Fool
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026 - Meyka
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - msn.com
Protagonist Therapeutics (NASDAQ:PTGX) Surges To New High Amid Nasdaq Today Focus - kalkinemedia.com
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 105.71 USD By Investing.com - Investing.com Australia
How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing - Stock Traders Daily
Protagonist Therapeutics stock hits all-time high at 105.71 USD - Investing.com
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data ReleaseLearn Why - simplywall.st
Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing - MarketScreener
Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing - MarketScreener
PTGX Forecast, Price Target & Analyst Ratings | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Reno Gazette Journal
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting - bitget.com
Protagonist presents one-year data for psoriasis drug ICOTYDE - Investing.com
Protagonist Therapeutics (MEX:PTGX) PE Ratio : At Loss (As of Mar. 28, 2026) - GuruFocus
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - msn.com
Arturo Md Molina Sells 15,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells $2,581,503.60 in Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 24,000 Shares of Stock - MarketBeat
Protagonist Therapeutics PTGX: chief medical officer sells $1.57 million By Investing.com - Investing.com Australia
Protagonist Therapeutics PTGX: Ali Asif sells $2.58 million in stock By Investing.com - Investing.com India
Protagonist Therapeutics PTGX: chief medical officer sells $1.57 million - Investing.com
Protagonist Therapeutics PTGX: Ali Asif sells $2.58 million in stock - Investing.com
Protagonist Therapeutics director Selick sells $2.52 million in shares By Investing.com - Investing.com India
Protagonist Therapeutics director Selick sells $2.52 million in shares - Investing.com
Protagonist Therapeutics Insiders Sold Shares Worth Over $6.7M - TradingView
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Vanguard disaggregates holdings; Protagonist Therapeutics (NASDAQ: PTGX) shows 0% ownership - Stock Titan
Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential? - Yahoo Finance
[144] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Asif Ali sells 54,791 PTGX shares; planned 24,765‑share option sale (PTGX) - Stock Titan
PTGX (NASDAQ: PTGX) insider files Form 144 to sell 15,000 shares - Stock Titan
US High Growth Tech Stocks to Watch Now - Sahm
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighHere's What Happened - MarketBeat
JPMorgan Chase & Co. Decreases Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Insider Sold Shares Worth $5,524,700, According to a Recent SEC Filing - marketscreener.com
Aug Chart Watch: Can Protagonist Therapeutics Inc be the next market leader2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Wall Street says Johnson and Johnson’s FDA-approved psoriasis drug should create 'significant value' for Protagonist Therapeutics - MSN
Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics(PTGX.US) Officer Sells US$5.52 Million in Common Stock - Moomoo
Protagonist therapeutics CEO sells $5.52 million in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):